Caisse DE Depot ET Placement DU Quebec Buys New Shares in Catalent, Inc.
| CTLT Stock | USD 63.10 0.14 0.22% |
Slightly above 55% of Catalent's investor base is interested to short. The analysis of overall sentiment of trading Catalent stock suggests that many investors are impartial at this time. Catalent's investing sentiment can be driven by a variety of factors including economic data, Catalent's earnings reports, geopolitical events, and overall market trends.
Catalent |
Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Catalent, Inc. during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The fund purchased 645,243 shares of the companys stock, valued at approximately ,082,000. Several other large investors
Read at thelincolnianonline.com
 |
Catalent Fundamental Analysis
We analyze Catalent's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalent using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalent based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Catalent is rated fifth in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Catalent Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Catalent stock to make a market-neutral strategy. Peer analysis of Catalent could also be used in its relative valuation, which is a method of valuing Catalent by comparing valuation metrics with similar companies.
Peers
Catalent Related Equities
| AMPH | Amphastar | 3.08 | ||||
| EBS | Emergent Biosolutions | 2.68 | ||||
| ALVO | Alvotech | 1.04 | ||||
| BHC | Bausch Health | 0.92 | ||||
| HLN | Haleon Plc | 0.83 | ||||
| ITCI | Intracellular | 0.05 | ||||
| CTLT | Catalent | 0.22 | ||||
| TAK | Takeda Pharmaceutical | 0.37 | ||||
| NBIX | Neurocrine Biosciences | 0.62 | ||||
| TEVA | Teva Pharma | 1.66 |
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.